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Abstract
Background: The activity of the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab
combined with oxaliplatin/leucovorin/5-fluorouracil (FUFOX) was assessed in first-line metastatic gastric and
oesophago-gastric junction (OGJ) cancer in a prospective phase II study showing a promising objective tumour
response rate of 65% and a low mutation frequency of KRAS (3%). The aim of the correlative tumour tissue studies
was to investigate the relationship between EGFR gene copy numbers, activation of the EGFR pathway, expression
and mutation of E-cadherin, V600E BRAF mutation and clinical outcome of patients with gastric and OGJ cancer
treated with cetuximab combined with FUFOX.
Methods: Patients included in this correlative study (n = 39) were a subset of patients from the clinical phase II
study. The association between EGFR gene copy number, activation of the EGFR pathway, abundance and
mutation of E-cadherin which plays an important role in these disorders, BRAF mutation and clinical outcome of
patients was studied. EGFR gene copy number was assessed by FISH. Expression of the phosphorylated forms of
EGFR and its downstream effectors Akt and MAPK, in addition to E-cadherin was analysed by
immunohistochemistry. The frequency of mutant V600E BRAF was evaluated by allele-specific PCR and the
mutation profile of the E-cadherin gene CDH1 was examined by DHPLC followed by direct sequence analysis.
Correlations with overall survival (OS), time to progression (TTP) and overall response rate (ORR) were assessed.
Results: Our study showed a significant association between increased EGFR gene copy number (≥ 4.0) and OS in
gastric and OGJ cancer, indicating the possibility that patients may be selected for treatment on a genetic basis.
Furthermore, a significant correlation was shown between activated EGFR and shorter TTP and ORR, but not
between activated EGFR and OS. No V600E BRAF mutations were identified. On the other hand, an interesting
trend between high E-cadherin expression levels and better OS was observed and two CDH1 exon 9 missense
mutations (A408V and D402H) were detected.
Conclusion: Our finding that increased EGFR gene copy numbers, activated EGFR and the E-cadherin status are
potentially interesting biomarkers needs to be confirmed in larger randomized clinical trials.
Trial registration: Multicentre clinical study with the European Clinical Trials Database number 2004-004024-12.
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Gastric cancer was estimated to be the fourth most com-
mon cancer and second leading cause of death from can-
cer worldwide in 2008 [1]. During recent decades, the
incidence of oesophago-gastric junction (OGJ) cancer has
increased continuously [2]. Metastatic gastric and OGJ
adenocarcinomas are characterised by poor prognosis
and modest response to chemotherapeutic treatment [3].
Despite recent improvements in the diagnostics and ther-
apy of these dismal diseases, new treatment options are
urgently needed to achieve clinical benefits for the
patients and improve their survival.
Recent advances in targeted therapy demonstrate the
advantage of a combination of trastuzumab, a monoclonal
antibody directed against the human epidermal growth
factor receptor 2 (HER2), with chemotherapy versus che-
motherapy alone in HER2-positive advanced gastric or
OGJ cancer [4]. Epidermal growth factor receptor (EGFR)
belongs to the same family of receptor tyrosine kinases
that plays a pivotal role in the regulation of tumour cell
growth and survival. Aside from HER2, EGFR may also be
a promising therapeutic target in gastric cancer. Several
studies have linked EGFR expression with advanced clini-
cal stage or the presence of distant metastasis and pro-
vided evidence that EGFR may have a central role in the
pathogenesis and prognosis of gastric and OGJ cancer
[5,6].
Cetuximab is a monoclonal human-mouse chimeric
antibody that interacts with domain III of the extracellular
region of EGFR with a high specificity and inhibits ligand-
induced activation [7]. Cetuximab has been approved for
the treatment of advanced colorectal cancer and for use in
combination with chemotherapy and with radiotherapy
for the treatment of squamous cell carcinoma of the head
and neck. In the first-line treatment of advanced gastric
and OGJ cancer, several phase II studies assessed cetuxi-
mab in combination with different chemotherapy regi-
mens, most of them showing promising results with
objective response rates ranging from 41 to 65% [8-11].
Cetuximab combined with FUFOX showed a high
response rate of 65% in first-line metastatic gastric and
OGJ cancer in a prospective phase II study [10]. The
expression level of EGFR on tumour cells was not corre-
lated with therapeutic response. The aim of the present
study was to investigate the relationship between EGFR
gene copy status, activation of the EGFR pathway, and the
BRAF mutation status with clinical outcome. Understand-
ing the molecular basis of therapy response may require the
analysis of additional markers such as the cell adhesion pro-
tein E-cadherin, which regulates epithelial-mesenchymal
transition and has been associated with cetuximab response
in preclinical models [12]. Therefore, the abundance of
E-cadherin was determined and E-cadherin gene (CDH1)
mutations were analysed.
Methods
Patient selection
The multicentre clinical study with the European Clini-
cal Trials Database number 2004-004024-12 enrolled 52
patients from seven active centres recruited from April
2005 until March 2006 [10].
As reported earlier [10], eligibility criteria included the
following: histologically confirmed metastatic or locally
advanced irresectable adenocarcinoma of the stomach or
OGJ; age 18 years or older; Eastern Cooperative Oncology
Group (ECOG) performance status ≤ 2; ≥ 1 unidimension-
ally measurable lesion ≥ 1 cm in diameter detected by
computed tomography (CT) scan or magnetic resonance
imaging (MRI); cardiac ejection fraction within normal
limits; absolute neutrophil count ≥ 2,000/μl; thrombocyte
count ≥ 100,000/μl; total bilirubin ≤ 1.5 × upper limit of
normal (ULN) and transaminases ≤ 2.5 × ULN; creatinine
clearance > 70 ml/min; no previous malignancy and no
chemotherapy except in the adjuvant or neoadjuvant
setting > 6 months before study entry.
Pretherapeutic tumour material (formalin-fixed and par-
affin-embedded) was obtained from 39 patients. Patients
presented with advanced disease not amenable to a cura-
tive therapeutic approach. Patients gave written informed
consent for translational investigations including tumour
genetic analyses concerning EGFR pathway-linked genes.
Data were acquired with approval from the ethics commit-
tee of the Technische Universität München.
Treatment
As reported earlier in detail [10], cetuximab was adminis-
tered at an initial dose of 400 mg/m
2 on day 1 over
120 mins, followed by weekly doses of 250 mg/m
2 over
60 mins. Oxaliplatin 50 mg/m
2 was given i.v. over 120 min
followed by folinic acid 200 mg/m
2 i.v. over 120 min and
5-fluorouracil 2,000 mg/m
2 i.v. over 24 h on days 1, 8, 15,
and 22, every 5 weeks (1 cycle). Treatment continued until
best response, or until there was evidence of disease pro-
gression, unacceptable toxicity, death, or withdrawal of
patient consent. Toxicity was graded according to National
Cancer Institute Common Toxicity Criteria (NCI-CTC,
version 3.0).
Response
Clinical response was determined by computer tomogra-
phy according to the Response Evaluation Criteria in
Solid Tumours (RECIST) as reported earlier [10].
Fluorescence in situ hybridisation
The EGFR gene copy status and the ploidy status of
chromosome 7 were evaluated in tumour specimen of
36 patients by image-based three-dimensional fluores-
cence in situ hybridisation (FISH). FISH analysis was
performed on 16-μm paraffin sections as previously
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Page 2 of 10described [13,14]. The commercially available LSI EGFR
SpectrumOrange/CEP 7 SpectrumGreen Dual Color
Probe (Abbott, Wiesbaden, Germany) was applied
according to the manufacturer’si n s t r u c t i o n s .S i g n a l s
were evaluated by optical sectioning and three-dimen-
sional imaging as previously described [15]. Tumours
were classified into the following categories with respect
to their mean EGFR gene copy numbers: (1) < 2.5 (nor-
mal), (2) ≥ 2.5- < 4.0 (low level copy number gain), (3)
≥ 4.0- < 6.0 (high level copy number gain), (4) ≥ 6.0
(amplification). Tumours were also classified into the
following categories with respect to their mean chromo-
some 7 centromeric signals (CEP7) copy numbers: (1) <
2.5, (2) ≥ 2.5- < 4.0, (3) ≥ 4.0- < 6.0 and (4) ≥ 6.0.
Antibodies
The following antibodies were used for immunohisto-
chemistry: anti-phosphorylated EGFR (pEGFR) rabbit
polyclonal antibody reacting with EGFR only when phos-
phorylated at tyrosine residue 1086 (#36-9700, obtained
from Zymed Laboratories, distributed by Invitrogen, Karls-
ruhe, Germany), anti-phosphorylated Akt (pAkt) mouse
monoclonal antibody recognising Akt phosphorylated at
Ser473 (#4051, Cell Signaling Technology, distributed by
New England Biolabs, Frankfurt, Germany), anti-phos-
phorylated p44/42 MAPK (pMAPK) rabbit polyclonal
antibody detecting p44/42 MAPK only when phosphory-
lated at Thr202/Tyr204 (#9101, Cell Signaling Technol-
ogy) and anti-E-cadherin mouse monoclonal antibody
HECD-1 (# ALX-804-201, Alexis Biochemicals, distributed
by Axxora Deutschland GmbH, Lörrach, Germany).
Immunohistochemical analysis
EGFR expression was determined using a standardised
immunohistochemistry assay (EGFR pharmDx Dako,
Glostrup, Denmark) as reported earlier [10]. A manual
staining protocol was used for pEGFR, pAkt, pMAPK and
E-cadherin as described in Additional file 1.
Reactivity score and interpretation of the
immunohistochemical staining
Evaluation of the immunhistochemical biomarker staining
was performed by at least two investigators (A.W. and B.
L.) who were unaware of clinical features and survival.
The reactivity score and the interpretation of the staining
are described in Additional file 1.
DNA extraction
The protocol for DNA extraction is available in Addi-
tional file 1.
BRAF mutation analysis
The BRAF hotspot mutation V600E was analysed using
allele-specific PCR following an established protocol
[16]. Positive and negative controls which had been
determined by direct sequencing were included in this
analysis.
CDH1 mutation analysis
Structural alterations of exons 2-16 of the CDH1 gene
were analysed in the tumours of 22 patients by denaturing
high performance liquid chromatography (DHPLC) as
described previously [17]. Upon detection of aberrant
DHPLC patterns, DHPLC analysis was followed by direct
sequencing of the PCR products. Additional information is
available in Additional file 1.
Statistical analysis
As reported earlier [10], the primary study endpoint was
the proportion of patients who responded to cetuximab-
FUFOX. The study was designed as a two-stage trial
assuming a response rate of ≤ 30% as not being of further
interest (null hypothesis) and a response rate of ≥ 50% as
interesting (alternative hypothesis). The best observed
response was taken as a basis for determination of the pri-
mary endpoint and confirmed responses were also
reported. Treatment with cetuximab plus FUFOX induced
objective tumour responses in 65% of treated patients
which was clearly above the threshold for accepting the
alternative hypothesis.
The calculation of TTP, OS, duration of treatment and
follow-up is explained in Additional file 1. Kaplan-Meier
survival time analysis was used to correlate the investi-
gated markers with TTP and OS. Differences in survival
between subgroups were compared by log-rank test. Cox
regression analysis was performed correlating the biomar-
kers with TTP and OS. Hazard ratios (HR) calculated by
the Cox proportional hazards model were reported with
95% CIs. The association between the biomarkers and
ORR or clinical benefit rate (CBR), respectively, was stu-
died using Fisher’se x a c ta n dc
2 tests when appropriate.
Correlation analysis between the investigated markers was
performed using the Pearson test and Spearman’s rho test.
At w o - s i d e dpv a l u el e s st h a n0 . 0 5w a sc o n s i d e r e dt ob e
statistically significant. The statistical analysis was carried
out with SPSS V17.0 software (SPSS Inc., Chicago, IL,
USA).
Results
Patient and tumour characteristics and clinical outcome
Patients with advanced gastric and OGJ cancer were a
subset of 52 patients who were enrolled in the clinical
trial between April 2005 and March 2006. Pretherapeu-
tic tumour material was available from 39 patients. The
location of the primary tumour was the OGJ in 22
(56%) patients and other parts of the stomach in the
remaining 17 (44%) patients (Table 1). As reported pre-
viously, all patients presented with metastatic disease,
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Page 3 of 10with lymph nodes, liver, peritoneum and lung as the
predominant metastatic sites [10]. The Laurén classifica-
tion of the tumours was intestinal in 22 (56%) cases and
non-intestinal (diffuse or mixed type) in 17 (44%) cases.
The median OS was 293 days (95% CI, 202 days to
384 days) with a 1-year survival rate of 38%. The med-
ian TTP was 230 days (95% CI, 144 days to 316 days)
with a probability of remaining progression-free at 1
year of 10%. The overall response rate (ORR; complete
response + partial response) of this patient subset was
62% (95% CI: 46-76%), including 3 complete and 20 par-
tial responses. Clinical benefit rate (CBR; complete
response + partial response + stable disease) was 81%
(95% CI: 66-90%). Median duration of treatment was
106 days; median follow-up was 379 days.
Relationship between EGFR gene copy numbers and
therapy response
EGFR gene copy numbers and CEP7 copy numbers were
determined by three-dimensional image-based FISH in
gastric and OGJ tumours from 36 patients. The range of
EGFR gene copy numbers was 2.0-8.2 (signals per
nucleus). Tumours were classified into four categories
with respect to their mean EGFR gene copy numbers.
The majority of tumours revealed EGFR low level copy
number gain (56%), while high level copy number gain
was less frequent (19%), and amplification was rare (3%)
( F i g u r e1 a ,T a b l e2 ) .T h eCEP7 copy numbers (signals
per nucleus) were in the range of 2.0-6.0. In most of the
tumours, low copy number changes for CEP7 (≥ 2.5- <
4.0) were observed (61%). The EGFR/CEP7 ratio was
within the range 0.7-1.5. The majority of patients were in
the group < 1.1 (61%).
EGFR gene copy numbers were correlated with CEP7
signals (Pearson test P < 0.001; Spearman’sr h ot e s tP <
0.001) and EGFR/CEP7 ratio (Pearson test P =0 . 0 1 3 ;
Spearman’s rho test P = 0.002) (Additional file 1: Supple-
mentary Tables S1 and S2).
Increased EGFR gene copy number (≥ 4.0) was signifi-
cantly associated with better OS (log-rank P = 0.011; HR
0.2, 95% CI: 0-0.8; P = 0.022) (Figure 1b, Additional file
1: Supplementary Table S3). Increased CEP7 gene copy
number (≥ 3.0 signals, aneusomy) was also related to OS
(log-rank P = 0.025; HR 0.4, 95% CI: 0.2-0.9; P = 0.030).
In contrast, it was not possible to define a cut-off point
that demonstrated a relationship between EGFR/CEP7
ratio and OS.
Copy numbers of the EGFR gene and CEP7 per se
were not associated with TTP (Additional file 1: Supple-
mentary Table S4). In contrast, the EGFR/CEP7 ratio
was significantly related to TTP using the Kaplan-Meier
method (log-rank P = 0.045), while the significance level
was not reached in univariate Cox regression analysis
(HR 0.4, 95% CI: 0.1-1.0; P = 0.056). No association was
found between EGFR and CEP7 gene copy number and
EGFR/CEP7 ratio with ORR or CBR (Additional file 1:
Supplementary Table S5).
Correlation between activation of the EGFR signalling
pathway and clinical outcome
Expression levels of the phosphorylated forms of EGFR
(pEGFR, Y1086), Akt kinase (pAkt, Ser473) and mitogen-
activated protein kinase (pMAPK, Thr202/Tyr204) were
determined by means of immunohistochemistry (Addi-
tional file 1: Supplementary Table S8). The examination
of the EGFR expression level was performed and pre-
viously reported [10]. The results obtained by this analy-
sis were included in the present study to search for
correlations with the presently analysed biomarkers and
clinical outcome. In total, pretherapeutic biopsies of 28
patients were available for the immunohistochemical
study. Staining of pEGFR was interpretable in 26 cases
(93%), pAkt in 28 cases (100%), pMAPK in 25 cases
(89%) and E-cadherin in 25 cases (89%).
Correlation analysis revealed a significant association
between EGFR and pEGFR expression (P =0 . 0 4 0 ,P e a r -
son test) (Additional file 1: Supplementary Table S1).
p E G F Rs t a i n i n gw a sn o tl i n k e dt op A k to rp M A P K
staining.
No statistically significant association between EGFR,
pEGFR, pAkt or pMAPK expression levels and OS was
found (Additional file 1: Supplementary Table S3).
Table 1 Patient and tumour characteristics
Characteristic No. of Patients
(n = 39)
%
Age (years)
Median 63
Range 38-80
Gender
Male 30 77
Female 9 23
ECOG performance status
01 6 4 1
11 7 4 4
26 1 5
Disease status
Locally advanced 0 0
Metastatic 39 100
Site of the primary tumour
Oesophago-gastric junction 22 56
Stomach 17 44
Histological classification (Laurén)
Intestinal 22 56
Non-intestinal (diffuse or mixed) 17 44
Abbreviation: ECOG Eastern Cooperative Oncology Group
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Page 4 of 10A significant correlation was shown between pEGFR and
shorter TTP (log-rank P =0 . 0 1 8 ;H R4 . 0 ,9 5 %C I :1 . 2 -
13.9, P = 0.027), but not between EGFR, pAkt or
pMAPK and TTP (Additional file 1: Supplementary
Table S4). The pEGFR expression level was associated
with ORR but not with CBR (Table 3, Additional file 1:
Supplementary Table S5): ORR was 31% in patients
with pEGFR-positive tumours and 92% in patients with
pEGFR-negative tumours (P = 0.004), clinical benefit
(CR, PR and SD) was achieved in 92% of patients who
presented with pEGFR-negative tumours and 62% of
patients with pEGFR-positive carcinomas (P =0 . 1 6 0 ) .
Median TTP was 121 days in patients with pEGFR-posi-
tive tumours and 291 days in patients with pEGFR-
negative tumours (P = 0.018). Median OS of patients
suffering from pEGFR positive tumours was 285 days
and 490 days in patients with pEGFR-negative tumours
(P = 0.619).
Oncogenic activation of EGFR downstream effectors in
the RAS-RAF-MAPK signalling pathway can negatively
influence cetuximab therapy. As reported earlier, KRAS
mutations were examined by direct sequencing of exon 2
[10]. One single KRAS mutation at nucleotide position 35
(G > A, Patient 36) that changes codon 12 from glycine
to aspartic acid (G12D) was detected in 1 of 32 patients
(3%, Table 4). The clinical benefit of the therapy was
stable disease, which means that the patient was, by defi-
nition, a non-responder (Additional file 1: Supplementary
Table S10). This KRAS mutation was previously
described in gastric cancer [18]. In addition, the hotspot
mutation V600E of the BRAF protein was analysed in the
present study using allele-specific PCR. No V600E BRAF
5 μm 
Figure 1 Detection of EGFR gene amplification and survival impact of EGFR copy number gain.( a) EGFR gene amplification (8.2 signals
per nucleus) was observed in one patient with OGJ cancer by image-based three-dimensional dual colour FISH analysis for EGFR (red) and
chromosome 7 (green). (b) Overall survival in metastatic gastric or OGJ cancer patients treated with cetuximab plus FUFOX was analysed with
the Kaplan-Meier method after stratification of patients according to EGFR gene copy numbers (cut-off 4.0). The log-rank test statistical analysis
indicates a statistically significant relationship (P = 0.011).
Table 2 EGFR gene copy analysis by three-dimensional FISH
No. of Patients (%), (n = 36)
Mean copy number < 2.5 ≥ 2.5- < 4.0 ≥ 4.0- < 6.0 ≥ 6.0
(normal) (low level) (high level) (amplification)
EGFR 8 (22%) 20 (56%) 7 (19%) 1 (3%)
CEP7 11 (31%) 22 (61%) 2 (6%) 1 (3%)
Ratio < 1.1 ≥ 1.1-1.5
EGFR/CEP7 22 (61%) 14 (39%)
Abbreviation: FISH fluorescence in situ hybridisation
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Page 5 of 10mutation was found in 32 patients (Table 4). Together,
the mutation frequency of key signalling molecules of the
RAS-RAF-MAPK pathway in this patient cohort was very
low.
Influence of the E-cadherin expression level or mutation
status on treatment outcome
To determine the contribution of expression or mutation
of E-cadherin to clinical outcome, immunohistochemical
detection of E-cadherin protein expression and mutation
profiling of exons 2-16 of the E-cadherin gene CDH1
were performed.
An interesting trend between high E-cadherin expres-
sion levels and increased OS was observed (log-rank P =
0.124; HR 0.3, 95% CI: 0.1-1.5, P = 0.141) (Additional
file 1: Supplementary Table S3, Figure 2a). No correla-
tions were found between E-cadherin expression and
TTP, ORR or CBR.
CDH1 missense mutations in exon 9 were detected in 2
of 22 tumours (9%), and several polymorphisms were
found in 4 of 22 tumours (18%) (Additional file 1: Sup-
plementary Table S9). In total, 15 of 22 analysed tumours
were of the non-intestinal type (diffuse or mixed type).
The CDH1 missense mutations occurred in 2 out of 15
tumours (13%) of these histological subtypes and were
diffuse-type signet cell ring gastric carcinomas. Both
mutations were confirmed by sequencing and not
detected in the adjacent normal tissues from the same
patients (Figure 2b).
The first tumour showed a CDH1 missense mutation in
exon 9 (Patient 27) at nucleotide position c1204 that
changes codon 402 from aspartic acid to histidine, thereby
affecting the putative calcium-binding motif DAD (DAD >
DAH). The second tumour harboured a novel CDH1 mis-
sense mutation in exon 9 (Patient 11) at nucleotide posi-
tion c1223 that changes codon 408 from alanine to valine.
Both tumours (with CDH1 missense mutation in exon
9) occurred in two female patients with peritoneal carci-
nogenesis. Due to early disease progression, their survival
times after first infusion with cetuximab were very short
(only 27 days for Patient 11 and 29 days for Patient 27).
Consequently, the response rate of Patient 11 was not
evaluable (Additional file 1: Supplementary Table S10).
Patient 27 was classified as a non-responder.
Discussion
Here, we report the results of a correlative research pro-
gram from a multicentre phase II study of cetuximab
plus weekly oxaliplatin, 5-fluorouracil and folinic acid in
first-line advanced gastric and OGJ cancer.
Predictive value of EGFR gene copy number gain
In gastric and OGJ cancer, the optimal cut-off points to
study an association between EGFR gene copy number
and clinical outcome during cetuximab treatment have
not been established. This fact explains the requirement of
a statistical search for the best cut-offs by correlating the
EGFR status with overall patient survival using the log
rank test. We found that the optimal cut-off value that
separated patients with favourable and unfavourable prog-
nosis was a mean number of 4.0 EGFR signals per nucleus.
We provide evidence that increased EGFR and CEP7
copy numbers were associated with better OS of
patients with metastatic gastric or OGJ cancer treated
with cetuximab and chemotherapy, but it was not possi-
b l et od e f i n eac u t - o f fp o i n tt h a ts h o w e dar e l a t i o n s h i p
between EGFR/CEP7 r a t i oa n dO S .A l t h o u g ht u m o u r
growth in responsive patients may be closely linked to
an increase in EGFR/CEP7 ratio, the literature in other
tumour entities, especially in metastatic colorectal can-
cer demonstrates the experimental difficulties in finding
a valid cut-off [19].
Several studies have shown a relationship between
specific molecular alterations of the EGFR gene, includ-
ing somatic mutations and copy number variations, and
the clinical activity of anti-EGFR drugs. Somatic EGFR
mutations have been reported to be the genetic events
underlying responsiveness of non-small cell lung cancer
to the small molecular EGFR-inhibitor gefitinib [20].
Table 4 Summary of mutation analysis
Gene No. of patients No. of mutations %
KRAS 32 1 3
BRAF 32 0 0
CDH1 22 2 9
Table 3 Clinical outcome according to pEGFR immunohistochemistry
pEGFR detectable pEGFR non detectable P value
Overall response rate
(CR and PR)
31% 92% 0.004*
Clinical benefit rate
(CR, PR and SD)
62% 92% 0.160*
Median time to progression 121 days 291 days 0.018**
Median overall survival 285 days 490 days 0.619**
*Fisher’s exact test, two-sided
**log-rank P
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Page 6 of 10Increased copy number of the EGFR gene is associated
with response to cetuximab in colorectal cancer patients
[21]. However, in gastric cancer, EGFR gene amplifica-
tion only occurs in a subset of patients in the range of
2-9% [22-24]. In accordance with these studies, we
found a low frequency of EGFR gene amplification (3%).
Interestingly, we detected a high frequency of EGFR low
copy gain (56%), which can only be reliably detected by
image-based three-dimensional FISH in thick (16 μm)
sections and not by standard FISH in thin (4 μm) sec-
tions, as was used in previous studies [15]. Notably, we
found that diploid cases in our study were predomi-
nantly of the intestinal type, and in contrast to the situa-
tion in colorectal cancer, the diploid genotype was not
predictive of therapy response. In accordance with the
low prevalence of genetic amplification of the EGFR
gene in this type of cancer, none of the 38 patients
exhibited increased EGFR gene copy number in a recent
phase II trial of cetuximab in combination with mFOL-
FOX6 in gastric and OGJ cancer [25].
Influence of the EGFR signalling cascade on patient
outcome
Because cetuximab binds to the extracellular domain of
EGFR, the obvious assumption was that the presence of
EGFR on gastric cancer cell membranes would be predic-
tive for response to cetuximab. However, the expression
level of EGFR on tumour cells per se, as determined by
immunohistochemistry, was not predictive of therapeutic
response in gastric and OGJ cancer in various phase II
trials of cetuximab in combination with chemotherapeu-
tic agents [8,10,25]. This observation is reminiscent of
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Figure 2 Survival impact of E-cadherin expression and sequence analysis of CDH1 exon 9 missense mutations.( a) Overall survival in
metastatic gastric or OGJ cancer patients treated with cetuximab plus FUFOX was analysed by the Kaplan-Meier method after stratification of
patients according to their E-cadherin expression level (score 0, 1+, 2+ versus 3+). The log-rank test statistical analysis indicates a trend between
high E-cadherin expression levels and increased OS (P = 0.124). (b) In the tumours of two patients, CDH1 exon 9 missense mutations were
detectable and caused amino acid changes D402H or A408V.
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Page 7 of 10the situation found in colorectal cancer, where immuno-
histochemical measurement of EGFR expression may not
be an accurate predictive factor for response to cetuxi-
mab therapy [26]. Notably, advanced gastric cancer
patients with EGFR expression in their tumours together
with low serum levels of the ligands EGF and transform-
ing growth factor-a showed better response in one study
[25]. Recent data on EGFR expression and clinical out-
come of patients treated with cetuximab plus irinotecan/
leucovorin/5-fluorouracil showed that tumour response
was more commonly found in advanced OGJ cancer
patients whose tumours expressed EGFR, although EGFR
expression was not associated with improved progres-
sion-free survival or overall survival [11]. Taken together,
the reports on EGFR expression and clinical outcome of
gastric and OGJ cancer patients treated with cetuximab
plus chemotherapy are not consistent.
Activation of EGFR triggers a signalling cascade that
comprises essentially two downstream pathways: the RAS-
RAF-MAPK axis is mainly involved in cell proliferation,
and the PI3K-Akt axis primarily controls cell survival [27].
T h er e s u l t so ft h ep r e s e n ts t u d ys u g g e s tt h a tt h ep E G F R
expression level was associated with clinical outcome. We
found that in patients with pEGFR-positive tumours, TTP
was significantly shorter compared with those patients
without detectable pEGFR in their tumours and that the
pEGFR expression level was associated with the ORR.
However, pEGFR expression was not significantly corre-
lated with OS. Differences in OS may have been blurred
by subsequent therapies not containing EGFR-antagonists.
In an attempt to better understand the mechanisms of
resistance to EGFR inhibitors, cell lines resistant to EGFR
inhibitors were reported to reveal elevated levels of
pEGFR, pAkt and signal transducer and activator of tran-
scription 3, which were associated with reduced apoptotic
capacity [28]. In our study, pEGFR expression was not cor-
related with pAkt or pMAPK expression, suggesting that
activation of the PI3K-Akt cascade and the MAPK path-
way occurred independently of EGFR.
Colorectal cancers lacking oncogenic alterations in genes
encoding EGFR downstream effectors such as KRAS,
BRAF, PIK3CA, and PTEN have the highest probability of
response to anti-EGFR therapies [27,29]. In contrast to col-
orectal cancer, the prevalence of KRAS mutations in gastric
cancer is low [22] and consequently, a relationship between
KRAS mutations and therapy response is difficult to estab-
lish. The frequency of KRAS mutations was between 0 and
9% in several phase II trials of cetuximab in combination
with chemotherapeutic agents in advanced gastric or OGJ
adenocarcinoma [9-11,25]. We did not detect any V600E
BRAF mutations in our study while the frequency of BRAF
mutations was 12% in the aforementioned study of cetuxi-
mab plus chemotherapy in advanced OGJ cancer patients
[11]. Together, in contrast to the situation in colorectal
cancer, oncogenic alterations in genes encoding signalling
molecules of the RAS-RAF-MAPK pathway are rare in gas-
tric and OGJ cancer.
Predictive role of E-cadherin expression and somatic
CDH1 gene mutations
Activation of EGFR is negatively influenced by E-cadherin-
mediated cell adhesion [30]. Therefore, we hypothesised
that E-cadherin affects the response to cetuximab plus
chemotherapy of gastric and OGJ cancer patients. We
found that patients with high expression of E-cadherin in
their tumours have an overall survival advantage com-
pared to patients with moderate or low expression. How-
ever, this result did not reach statistical significance,
presumably due to the low number of investigated
patients. In several studies, cancer cell lines with high E-
cadherin expression levels were found to be more suscep-
tible to cetuximab or other anti-EGFR agents than cell
lines with low E-cadherin levels [12,31].
Because E-cadherin mutations are frequently detected
in somatic and germline diffuse-type gastric cancer
[17,32], we also decided to assess whether the CDH1
mutation status is crucial to predict clinical outcome. We
have previously shown that certain CDH1 mutations
have a negative influence on survival of gastric carcinoma
patients [33] and that CDH1 mutations are associated
with enhanced EGFR activation [34,35].
We detected the CDH1 mutations D402H and A408V in
diffuse-type signet cell ring gastric carcinomas, confirming
previous observations that CDH1 mutations are associated
with diffuse- or mixed-type gastric cancer but not with
intestinal gastric carcinoma [32]. The first of these muta-
tions has been described previously at the amino acid level
b u ta tad i f f e r e n tn u c l e o t i d ep o s i t i o n[ 3 6 ] .T h es e c o n d
mutation has not been previously described. The total fre-
quency of CDH1 mutations in exons 2-16 that were
observed in our study was 9% for all investigated tumours
and 13% when only diffuse and mixed-type gastric carci-
nomas were taken into account. CDH1 mutation frequen-
cies for advanced diffuse-type gastric carcinomas reported
from other studies are 28% [37], 50% [32] and 70% [38].
Due to the low mutation frequency and early disease pro-
gression observed here, a correlation between the occur-
rence of CDH1 mutations and clinical outcome cannot be
calculated.
The prognostic significance of E-cadherin expression in
gastric carcinoma is under controversial discussion
[39,40]. To our knowledge, this study is the first to assess
the abundance and genetic mutation of E-cadherin as bio-
markers of response to EGFR-targeted therapy. Larger stu-
dies are required to assess the contribution of E-cadherin
expression and CDH1 mutations to clinical outcome of
gastric and OGJ cancer patients treated with anti-EGFR
therapy.
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Specific alterations of the EGFR gene, including copy
number variations, and oncogenic activation of EGFR
downstream effectors such as KRAS and BRAF had been
previously reported as the genetic events underlying the
response to cetuximab plus chemotherapy in colorectal
cancer. Our study showed an association between EGFR
gene copy number and survival in gastric and OGJ cancer,
suggesting that patients may be selected for treatment on
a genetic basis. A significant correlation was shown
between pEGFR and shorter TTP, but not between
pEGFR and OS. On the other hand, an interesting trend
between high E-cadherin expression levels and better OS
was observed and two CDH1 missense mutations in exon
9 (A408V and D402H) were identified. However, due to
the low mutation frequency and early disease progression,
the relationship between the occurrence of CDH1 muta-
tions and clinical outcome could not be assessed.
Taken together, we consider the EGFR gene copy status,
activated EGFR and E-cadherin as promising candidate
biomarkers. Due to the small number of patients studied,
this trial has to be considered as a hypothesis-generating
study and the results need to be confirmed in independent
randomized clinical trials.
The efficacy of cetuximab plus capecitabine and cisplatin
in advanced gastric and OGJ cancer is currently being
investigated in the multinational “Erbitux in combination
with Xeloda and cisplatin in advanced esophago-gastric
cancer” (EXPAND) phase III trial (NCT00678535).
Additional material
Additional file 1: The file Supplementary-BMC Cancer in the PDF
format contains supplementary results, methods and tables.
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